Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

CRISPR used to uncover new drug targets for cancer

02 October 2017

By Rachel Reeves

Appeared in BioNews 920

New potential drug targets have been identified for cancers associated with KRAS gene mutations, which are thought to drive around 20-30 percent of all human cancers.

Researchers used CRISPR genome editing to identify two genesNADK and KHK, which markedly reduced the growth of human colorectal cancer cells with KRAS mutations when inactivated in a mouse model. The team also found new 'tumour suppressor' genes – those involved in keeping cancers at bay.

'One of the most surprising findings from our study is how performing this type of genetic screen directly in a mammalian microenvironment revealed not only new synthetic lethal interactions, but also new tumour suppressor genes that are dependent on KRAS mutations,' said Dr Edwin Yau of the University of California San Diego (UCSD), and first author of the study.

Cancers caused by KRAS mutations include lung, pancreatic and colorectal cancer - often the most lethal and difficult to treat.

While previous research has focused on directly targeting mutant KRAS proteins to treat cancer, with limited success, researchers at the UCSD's School of Medicine decided to search for other genes which kill KRAS-mutated cancer cells when inhibited.

The team used genome editing to systematically inactivate every gene in the genomes of two human colorectal cancer cell lines with and without the KRAS mutation.

They then investigated whether inactivating these genes affected the ability of the cancer cells to grow in mice.

Inhibiting NADK and KHK, which code for metabolic enzymes, reduced the growth of KRAS-mutant colorectal cancer cells in mice by about 50 percent. There was no effect on cells with normal KRAS.

Crucially, the team saw these results only when the cancer cells were grown in mice rather than in vitro. The mammalian system provides 'a more realistic microenvironment where the tumour has to survive' explained Dr Tariq Rana, who led the study.

The researchers also found other genes that, when inactivated, had the opposite effect of NADK and KHK. These tumour suppressor genes increased the growth of KRAS-mutant tumours, but not of normal KRAS tumours. 

The team now want to carry out further research to better understand how KRAS-mutant cancers develop.

The study was published in Cancer Research.


The latest developments in genome editing will be discussed at the session 'What Next for Genome Editing? Politics and the Public', at the Progress Educational Trust's upcoming public conference 'Crossing Frontiers: Moving the Boundaries of Human Reproduction'.

The conference is taking place in London on Friday 8 December 2017. Full details - including sessions, speakers and how to book your place - can be found here.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

18 September 2017 - by Dr Molly Godfrey 
Organoids and CRISPR/Cas9 have been combined in a novel method to study genetic mutations occurring in cancer...
14 August 2017 - by Ebtehal Moussa 
Over a 100 new genes that may be essential for cancer immunotherapy to work have been identified using a new CRISPR-based screen...
15 May 2017 - by Isobel Steer 
Cancer-related mutations have been found in tissue taken from patients with deep endometriosis...
24 April 2017 - by Jennifer Willows and Annabel Slater 
A new highly sensitive diagnostic system for diseases has been adapted from CRISPR...
12 December 2016 - by Ayala Ochert and Ebtehal Moussa 
Researchers have successfully treated a woman with colon cancer using her own immune cells to target a cancer-causing gene that had previously been considered 'undruggable'...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation